수의용 백신 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the veterinary vaccines market size was valued at USD 10.30 billion in 2025 and is estimated to grow from USD 11.17 billion in 2026 to reach USD 16.80 billion by 2031, at a CAGR of 8.49% during the forecast period (2026-2031).

This report is Segmented by Animal Type (Livestock Animal Vaccines, Companion Animal Vaccines), Technology (Live Attenuated, Toxoid, and More), Disease Indication (FMD, Newcastle Disease, and More), Route of Administration (Parenteral, Oral, and More), Distribution Channel (Veterinary Hospitals & Clinics, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Veterinary Vaccines Market Trends and Insights

Growing Transboundary Livestock Outbreaks

Cross-border animal diseases now behave like rolling demand shocks, permanently raising baseline vaccination volumes. The World Organisation for Animal Health logged 4,782 highly pathogenic avian influenza events across 76 countries during 2024-2025, including first-ever detections in United States dairy herds that led to the cull of more than 100 million poultry. Germany confirmed its first domestic ASF case in June 2024, and the Philippines lost 15% of its swine inventory in the same period. These crises pushed the FAO and WOAH to launch a USD 500 million ASF control pathway in 2025, locking in multi-year vaccine contracts that are insensitive to price swings.

Rising Companion-Animal Ownership and Spend

United States households owned 89.7 million dogs and 73.8 million cats in 2025, yet veterinary spending declined 4% year over year as owners embraced telemedicine and online pharmacies. Many states now allow licensed practitioners to prescribe core vaccines through video consultations, enabling e-commerce platforms to dispatch rabies and distemper boosters directly to homes. However, just 57.3% of cat owners saw a veterinarian in 2025, suggesting feline coverage remains suboptimal. Manufacturers that hope to capture the 12.32% CAGR e-commerce channel must therefore invest in consumer education that explains the preventive value of timely shots.

Cold-Chain Gaps in Emerging Markets

The FAO estimates that up to 40% of livestock doses in sub-Saharan Africa lose potency before use because transport exceeds 8 °C for extended periods. Thermostable DNA formats hold promise, but national authorities often lack the capacity to evaluate stability dossiers, prolonging registration by as much as five years. Until uniform standards emerge, poor infrastructure will cap penetration in hot climates.

Other drivers and restraints analyzed in the detailed report include:

1. Government-Funded Mass-Vaccination Programs
2. Commercial Poultry Integration Boosting Biosecurity Demand
3. Shortage of Large-Animal Veterinarians and Vaccinators

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Livestock products captured 63.55% of the Veterinary vaccines market share in 2025, and the segment is projected to grow at a 9.85% CAGR as antimicrobial resistance drives the phase-out of routine antibiotics. Bovine programs remain buoyed by state-funded brucellosis and FMD eradication drives in India, Brazil, and several African nations. Porcine autogenous formulations, licensed on a farm-by-farm basis in the United States, let producers match viral drift faster than commercial updates. Poultry doses dominate volume terms because hatchery spray and in-ovo injection protocols deliver near-universal coverage for day-old chicks.

Companion-animal vaccines held 36.45% in 2025 but confront headwinds from longer booster intervals and telemedicine's partial substitution for in-clinic care. Core canine rabies and distemper injections remain mandatory in most jurisdictions, anchoring a steady revenue floor, yet discretionary products such as Lyme disease boosters lose ground to antibody titre testing. Feline uptake trails canine because indoor cats are perceived as lower risk, a gap that suppliers hope to close through direct-to-consumer education.

Live attenuated formats owned 50.53% of revenue in 2025, reflecting decades of use in poultry and cattle. The Veterinary vaccines market for recombinant and subunit products is expected to grow rapidly, expanding at a 10.75% CAGR through 2031 as eradication campaigns demand DIVA compliance. Recombinant ASF candidates approved in Europe delete diagnostic target genes, allowing herds to prove freedom from infection and regain export access.

Inactivated doses continue to serve pregnant animals and regions wary of reversion risk, though multi-shot protocols inflate labor costs. DNA, mRNA, and VLP technologies occupy an emerging niche supported by guidelines issued in 2024, yet production expenses remain five to ten times higher than conventional lines. Wider rollout depends on manufacturing scale and streamlined approval pathways in the Asia-Pacific.

Complete Report Scope:

• By Animal Type
  • Livestock Animal Vaccines
    • Bovine
    • Porcine
    • Poultry
    • Other Livestock (Small Ruminants, Aquaculture, etc.)
  • Companion Animal Vaccines
    • Canine
    • Feline
    • Equine
• By Technology
  • Live Attenuated
  • Inactivated / Killed
  • Toxoid
  • Recombinant / Sub-unit
  • Other Technologies (DNA, mRNA, VLP, etc.)
• By Disease Indication
  • Foot-and-Mouth Disease (FMD)
  • Newcastle Disease
  • Porcine Reproductive & Respiratory Syndrome (PRRS)
  • Rabies
  • Brucellosis
  • Avian Influenza
  • Canine Parvovirus
  • Other Indications
• By Route of Administration
  • Parenteral (Injection)
  • Oral
  • Intranasal
  • Transdermal / Needle-free
  • Other Routes
• By Distribution Channel
  • Veterinary Hospitals & Clinics
  • Retail Pharmacies & Agri-Stores
  • Online / e-Commerce
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 32.62% of global revenue in 2025, supported by vertically integrated poultry systems that vaccinated more than 9 billion broilers during the year. Companion-animal saturation and declining clinic visits limit upside, yet emergency funding worth USD 824 million for HPAI during 2024-2025 produced a temporary spike in orders. Mexico's expanding pork and poultry sectors promise incremental growth once cold-chain improvements roll out.

Asia-Pacific is the fastest-growing territory, registering a 9.72% CAGR to 2031. China's hog-herd reconstruction after ASF and India's public procurement of FMD and brucellosis vaccines underpin demand. Japan and South Korea enforce mandatory poultry vaccination to improve volume stability, while Australia and New Zealand focus on export-oriented livestock that must meet stringent health rules at destination markets.

Europe benefits from regulatory leadership, having released DNA-vaccine guidelines in 2024 and approved recombinant ASF candidates in 2025. Germany, France, and Spain dominate usage due to large animal populations, though overall herd sizes continue to shrink under environmental policy pressure. The United Kingdom's GBP 12.5 million vaccine initiative indicates a post-Brexit drive for sovereign production.

The Middle East and Africa are catching up as FAO-backed programs subsidize doses in least-developed economies. The GCC is investing in domestic biomanufacturing, led by Saudi Arabia's new National Center for Animal Health facility. South America grows on the back of Brazil's poultry exports and Argentina's fast-rising swine capacity, both of which must document vaccination for Asian buyers.

1. AdvaCare Pharma USA LLC
2. Bimeda Biologicals, LLC
3. Biogenesis Bago S.A.
4. Boehringer Ingelheim
5. Ceva Sante Animale S.A.
6. Colorado Serum Company
7. Elanco
8. Hester Biosciences
9. HIPRA, S.A.
10. Huvepharma
11. Indian Immunologicals
12. Laboratorios Calier, S.A.
13. Merck & Co., Inc. (MSD Animal Health)
14. Neogen
15. Ourofino Saude Animal
16. Phibro Animal Health
17. Qingdao Yebio Bioengineering Co., Ltd.
18. Vaxxinova International B.V.
19. Virbac S.A.
20. Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Transboundary Livestock Outbreaks
  • 4.2.2 Rising Companion-Animal Ownership and Spend
  • 4.2.3 Government-Funded Mass-Vaccination Programs
  • 4.2.4 Commercial Poultry Integration Boosting Biosecurity Demand
  • 4.2.5 Precision-Livestock Analytics Enabling Micro-Targeted Immunization
  • 4.2.6 Emergence of Autogenous and Thermostable Vaccines Amid AMR Curbs
• 4.3 Market Restraints
  • 4.3.1 Cold-Chain Gaps in Emerging Markets
  • 4.3.2 Shortage of Large-Animal Veterinarians and Vaccinators
  • 4.3.3 Regulatory Bottlenecks for Novel Vector and Mrna Veterinary Vaccines
  • 4.3.4 Rising Anti-Vaccination Sentiment among Smallholders
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Animal Type
  • 5.1.1 Livestock Animal Vaccines
    • 5.1.1.1 Bovine
    • 5.1.1.2 Porcine
    • 5.1.1.3 Poultry
    • 5.1.1.4 Other Livestock (Small Ruminants, Aquaculture, etc.)
  • 5.1.2 Companion Animal Vaccines
    • 5.1.2.1 Canine
    • 5.1.2.2 Feline
    • 5.1.2.3 Equine
• 5.2 By Technology
  • 5.2.1 Live Attenuated
  • 5.2.2 Inactivated / Killed
  • 5.2.3 Toxoid
  • 5.2.4 Recombinant / Sub-unit
  • 5.2.5 Other Technologies (DNA, mRNA, VLP, etc.)
• 5.3 By Disease Indication
  • 5.3.1 Foot-and-Mouth Disease (FMD)
  • 5.3.2 Newcastle Disease
  • 5.3.3 Porcine Reproductive & Respiratory Syndrome (PRRS)
  • 5.3.4 Rabies
  • 5.3.5 Brucellosis
  • 5.3.6 Avian Influenza
  • 5.3.7 Canine Parvovirus
  • 5.3.8 Other Indications
• 5.4 By Route of Administration
  • 5.4.1 Parenteral (Injection)
  • 5.4.2 Oral
  • 5.4.3 Intranasal
  • 5.4.4 Transdermal / Needle-free
  • 5.4.5 Other Routes
• 5.5 By Distribution Channel
  • 5.5.1 Veterinary Hospitals & Clinics
  • 5.5.2 Retail Pharmacies & Agri-Stores
  • 5.5.3 Online / e-Commerce
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AdvaCare Pharma USA LLC
  • 6.3.2 Bimeda Biologicals, LLC
  • 6.3.3 Biogenesis Bago S.A.
  • 6.3.4 Boehringer Ingelheim International GmbH
  • 6.3.5 Ceva Sante Animale S.A.
  • 6.3.6 Colorado Serum Company
  • 6.3.7 Elanco Animal Health Incorporated
  • 6.3.8 Hester Biosciences Limited
  • 6.3.9 HIPRA, S.A.
  • 6.3.10 Huvepharma
  • 6.3.11 Indian Immunologicals Ltd.
  • 6.3.12 Laboratorios Calier, S.A.
  • 6.3.13 Merck & Co., Inc. (MSD Animal Health)
  • 6.3.14 Neogen Corporation
  • 6.3.15 Ourofino Saude Animal
  • 6.3.16 Phibro Animal Health Corporation
  • 6.3.17 Qingdao Yebio Bioengineering Co., Ltd.
  • 6.3.18 Vaxxinova International B.V.
  • 6.3.19 Virbac S.A.
  • 6.3.20 Zoetis Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment